Susquehanna Portfolio Strategies
ADCT icon

Susquehanna Portfolio Strategies’s ADC Therapeutics ADCT Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.9K Sell
28,864
-35,659
-55% -$104K ﹤0.01% 830
2026
Q1 		$242K Hold
64,523
– – ﹤0.01% 880
2025
Q4 		$228K Hold
64,523
– – ﹤0.01% 928
2025
Q3 		$258K Buy
64,523
+21,097
+49% +$66.5K ﹤0.01% 944
2025
Q2 		$116K Buy
+43,426
New +$91.3K ﹤0.01% 815

Other funds holding ADCT

Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Susquehanna Portfolio Strategies's ADCT Position: Q2 2026 in Review

Susquehanna Portfolio Strategies reduced its ADC Therapeutics (ADCT) stake by 55% in Q2 2026, selling an estimated $104K and leaving 28,864 shares worth $30.9K. The position accounts for ﹤0.01% of the portfolio, ranked #830.

Susquehanna Portfolio Strategies first reported a position in ADCT in Q2 2025 and has held it in 5 quarters since. The position peaked at $258K in Q3 2025. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Susquehanna Portfolio Strategies held 28,864 shares of ADC Therapeutics worth $30.9K as of Q2 2026.
  • Susquehanna Portfolio Strategies sold 35,659 ADC Therapeutics shares in Q2 2026, an estimated $104K.
  • ADC Therapeutics made up ﹤0.01% of Susquehanna Portfolio Strategies's portfolio in Q2 2026, its #830 holding.
  • Susquehanna Portfolio Strategies first reported a position in ADC Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Susquehanna Portfolio Strategies's ADC Therapeutics position peaked at $258K in Q3 2025.
  • 113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.